Skip to main content

Table 1 Established prostate cancer susceptibility alleles

From: Prostate cancer genomics: can we distinguish between indolent and fatal disease using genetic markers?

dbSNP number Chromosome Genea Risk alleleb Study
rs1465618 2p21 THADA A Eeles et al. 2009 [21]
rs721048 2p15 EHBP1 A Gudmundsson et al. 2008 [27]
rs12621278 2q31.1 ITGA6 A Eeles et al. 2009 [21]
rs4857841 3q21.3 EEFSEC A Gudmundsson et al. 2009 [57]
rs12500426 4q22.3 PDLIM5 A Eeles et al. 2009 [21]
rs17021918 4q22.3 PDLIM5 C Eeles et al. 2009 [21]
rs7679673 4q24 FLJ20032 C Eeles et al. 2009 [21]
rs9364554 6q25.3 SLC22A3 T Eeles et al. 2008 [28]
rs10486567 7p15.2 JAZF1 G Thomas et al. 2008 [26]
rs6465657 7q21.3 LMTK2 C Eeles et al. 2008 [28]
rs1512268 8p21.2 NKX3-1 T Eeles et al. 2009 [21]
rs12543663 8q24.21   C Al Olama et al. 2009 [16]
rs10086908 8q24.21   T Al Olama et al. 2009 [16]
rs1016343 8q24.21   T Al Olama et al. 2009 [16]
rs13252298 8q24.21   A Al Olama et al. 2009 [16]
rs6983561 8q24.21   C Al Olama et al. 2009 [16]
rs16901979 8q24.21   A Gudmundsson et al. 2007 [11]
rs16902094 8q24.21   G Gudmundsson et al. 2009 [57]
rs445114 8q24.21   T Gudmundsson et al. 2009 [57]
rs620861 8q24.21   C Al Olama et al. 2009 [16]
rs6983267 8q24.21   G Al Olama et al. 2009 [16]
rs1447295 8q24.21   A Amundadottir et al. 2006 [9]
rs10993994 10q11.23 MSMB T Eeles et al. 2008 [28]
rs4962416 10q26.13 CTBP2 C Thomas et al. 2008 [26]
rs7127900 11p15.5   A Eeles et al. 2009 [21]
rs12418451 11q13.2   A Zheng et al. 2009 [34]
rs11228565 11q13.2   A Gudmundsson et al. 2009 [57]
rs10896449 11q13.2   G Thomas et al. 2008 [26]
rs11649743 17q12 HNF1B G Sun et al. 2008 [30]
rs4430796 17q12 HNF1B A Gudmundsson et al. 2007 [11]
rs1859962 17q24.3   G Gudmundsson et al. 2007 [11]
rs8102476 19q13.2 PPP1R14A C Gudmundsson et al. 2009 [57]
rs2735839 19q13.33 KLK3 A Eeles et al. 2008 [28]
rs9623117 22q13.1 TNRC6B C Sun et al. 2009 [31]
rs5759167 22q13.2 BIK G Eeles et al. 2009 [21]
rs5945619 Xp11.22 NUDT11 C Eeles et al. 2008 [28]
  1. aGenes within the linkage-disequilibrium block defined by the associated variant: BIK, BCL2-interacting killer; CTBP2, C-terminal binding protein 2 isoform 2; EEFSEC, elongation factor for selenoprotein translation; EHBP1, EH domain binding protein 1; FLJ20032, hypothetical protein LOC54790; HNF1B, hepatocyte nuclear factor 1 homeobox B; ITGA6, integrin alpha chain 6; JAZF1, juxtaposed with another zinc finger gene 1; KLK3, kallikrein 3; LMTK2, lemur tyrosine kinase 2; MSMB, β-microseminoprotein isoform a precursor; NKX3-1, NK3 transcription factor related locus 1; NUDT11, nudix-type motif 11; PDLIM5, PDZ and LIM domain 5 isoform d; PPP1R14A, protein phosphatase 1 regulatory inhibitor; SLC22A3, solute carrier family 22 member 3; SLC25A37, mitochondrial solute carrier protein; THADA, thyroid adenoma associated isoform 1; TNRC6B, trinucleotide repeat containing 6B isoform 2. bRisk alleles as defined from published data cited in the column.